Despite the decline of its prescription, Baraclude still stays in the top… Viread is chasing aggresively
The hepatitis B drug, ‘Viread’ emerging as a star from a dark horse, has been accelerated to catch ‘Baraclude’.
According to the Medipana News’s accumulated results created based on the UBIST’s
data of collective prescriptions of 30 main products on the third quarter in 2014, the top 5 products ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
